Mostrando 3 resultados de: 3
Bisphosphonates or denosumab discontinuation and risk of fractures: Response to the Letter by Anastasilakis et al.
OtherAbstract:Palabras claves:Autores:Anagnostis P., Ceausu I., Depypere H., Faustino R. Pérez-López, Goulis D.G., Lambrinoudaki I., Mintziori G., Mueck A., Paschou S.A., Rees M., Senturk L.M., Simoncini T., Stevenson J.C., Stute P., Trémollieres F.A.Fuentes:scopusEMAS position statement: Testosterone replacement therapy in the aging male
ArticleAbstract: Introduction Late-onset hypogonadism (LOH) represents a common clinical entity in aging males, charaPalabras claves:Aging male, Late-onset hypogonadism, Testosterone replacementAutores:Ceausu I., Depypere H., Dimopoulou C., Faustino R. Pérez-López, Goulis D.G., Lambrinoudaki I., Mueck A., Rees M., Senturk L.M., Simonsini T., Stevenson J.C., Stute P., van der Schouw Y.T.Fuentes:scopusDrug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement
ReviewAbstract: Background Bisphosphonates and denosumab are used extensively in the treatment of postmenopausal ostPalabras claves:Alendronate, Bisphosphonates, Denosumab, Drug holiday, Risedronate, Zoledronic acidAutores:Anagnostis P., Ceausu I., Depypere H., Faustino R. Pérez-López, Goulis D.G., Lambrinoudaki I., Mintziori G., Mueck A., Paschou S.A., Rees M., Senturk L.M., Simoncini T., Stevenson J.C., Stute P., Trémollieres F.A.Fuentes:scopus